Effect of IV Selenium on Severe Traumatic Brain Injury prognosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014010112776N2

Enrollment

100

Registered

2014-01-12

Start date

2014-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TBI.

Interventions

Intervention 1: IV Selenium 1000mg QD x 5 days + 500mg QD x 5days in randomly assigned patients. Intervention 2: Normal Saline as placebo in same size and time sequence.

Treatment - Drugs

Placebo

IV Selenium 1000mg QD x 5 days + 500mg QD x 5days in randomly assigned patients

Normal Saline as placebo in same size and time sequence

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: acute sever TBI (GCS 5-8). Exclusion criterion:death in first 48 hours.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Glasgow Outcome Scale Extended. Timepoint: 6 month. Method of measurement: Physical exam.	—

Secondary

Measure	Time frame
Hospital & ICU Length Of Stay. Timepoint: during hospital course. Method of measurement: chart review.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHosseinali Khalili

Shiraz Neurosciences Research Center

khalili_h@sums.ac.ir+98 71 1623 4508

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026